retatrutide maximum dose clinical trials Dosing Schedule: From to Real Weight Loss Outcomes Tirzepatide vs. Retatrutide: Key Differences

weight loss in real-world settings may differ

Compounded GLP-1 options allow for microdosing and personalized escalation, which can enhance safety in higher-risk populations when supervised by a qualified healthcare provider

Some people experience only mild effects while others need extra support from their prescribing team to manage symptoms

The key difference is retatrutide's dysesthesia (20.9%) versus less than 1% with Wegovy or Mounjaro

Writing a GLP-1 prescription without medical indication or supervision could lead to adverse reactions and severe side effects for patients, and the physician runs the risk of losing their medical license

Retatrutide remains unlicensed by the MHRA and EMA as of mid-2025